RVLP(Delisted)
RVL Pharmaceuticals·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RVLP
Rvl Pharmaceuticals Plc
A specialty pharmaceutical company focused on commercializing the treatment of acquired blepharoptosis, or low-lying eyelid, in adults
400 Crossing Boulevard, Bridgewater, NJ 08807
--
RVL Pharmaceuticals plc was incorporated as a private limited company under the laws of Ireland on 13 July 2017. The Company is a specialty pharmaceutical company focused on the development and commercialization of products targeting underserved patient populations in ophthalmic medicine and medical aesthetic treatments. In July 2020, the company received FDA regulatory approval for RVL-1201, or Upneq (oxymetazoline hydrochloride eye drops), 0.1%, for the treatment of adult acquired ptosis, or ptosis or drooping eyelids.
Company Financials
EPS
RVLP has released its 2023 Q2 earnings. EPS was reported at -0.1, versus the expected -0.13, beating expectations. The chart below visualizes how RVLP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RVLP has released its 2023 Q2 earnings report, with revenue of 8.26M, reflecting a YoY change of -2.25%, and net profit of -23.89M, showing a YoY change of -97.33%. The Sankey diagram below clearly presents RVLP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
